KEN SAIJO

J-GLOBAL         Last updated: Oct 11, 2019 at 15:50
 
Avatar
Name
KEN SAIJO

Research Interests

 
 

Research Areas

 
 

Published Papers

 
A Concise Approach for Producing Optically Pure Carboxylic Acid Segments for the Synthesis of Bicyclic Depsipeptide Histone Deacetylase Inhibitors
Koichi Narita, Noel Sayar, Ken Saijo, Chikashi Ishioka, Tadashi Katoh
Synthesis   51 1408-1418   May 2019   [Refereed]
Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study.
Saijo K, Imai H, Ouchi K, Okada Y, Sato Y, Komine K, Takahashi M, Takahashi S, Shirota H, Takahashi M, Ishioka C.
Tohoku J Exp Med.   248(1) 37-43   May 2019   [Refereed]
In Vitro and in Vivo antitumor activity and the mechanism of siphonodictyal B in human colon cancer cells.
Chikamatsu S, Saijo K, Imai H, Narita K, Kawamura Y, Katoh T, Ishioka C.
Cancer Med   8 5662-5672   2019   [Refereed]
Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer. Cancer Manag Res
Imai H, Saijo K, Komine K, Kawamura Y, Hiraide S, Umegaki S, Okada Y, Ohuchi K, Sato Y, Takahashi M, Takahashi S, Shirota H, Takahashi M, Ishioka C
Cancer Manag Res   17(10) 3629-3636   2018   [Refereed]
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)
Tahara M, Kiyota N, Yokota T, Hasegawa Y, Muro K, Takahashi S, Homma A, Taguchi J, Suzuki M, Minato K, Yane K, Ueda S, Hara H, Saijo K, Yamanaka T
Ann Oncol   29(4) 1004-1009   2018   [Refereed]
IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model
Ito SE, Shirota H, Kasahara Y, Saijo K, Ishioka C
Cancer Immunol Immunother   66(11) 1485-1496   Nov 2017   [Refereed]
Efficacy and safety of denosumab versus zoledronic acid in delaying skeletal-related events in patients with gastrointestinal cancer, pancreas-biliary system cancer, and other rare cancers
Hiroo Imai, Ken Saijo, Kota Ohuchi, TYoshinari Okada, KeigoKomine, Masahiro Takahashi, Shin Takahasi, Masanobu Takahashi, Hideki Shimodaira, Chikashi Ishioka
Journal of Bone Oncol   6 37-40   2017   [Refereed]
Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor
Saijo K, Imai H, Chikamatsu S, Narita K, Katoh T, Ishioka C
Cancer Sci   108(7) 1469-1475   2017   [Refereed]
Enantioselective Total Synthesis of (–)-Siphonodictyal B and (+)-8-epi-Siphonodictyal B with Phosphatidylinositol 3-Kinase α (PI3Kα) Inhibitory Activity
Takuya Kikuchi, Koichi Narita, Ken Saijo, Chikashi Ishioka, Tadashi Katoh
Eur. J. Org. Chem   5659-5666   2016   [Refereed]
Biological, biochemical and structural properties of romidpsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors
4. Saijo K, Imamura J, Narita K, Oda A, Shimodaira H, Katoh T, and Ishioka C
Cancer Science   106 208-215   2015   [Refereed]
Predicting the structures of complexes between phosphoinositide 3-kinase (PI3K) and romidepsin-related compounds for the drug design of PI3K/histone deacetylase dual inhibitors using computational docking and the ligand-based drug design approach
5. Oda A, Saijo K, Ishioka C, Narita K, Katoh T, Watanabe Y, Fukuyoshi S, Takahashi O
J Mol Graph Model   54 46-53   2014   [Refereed]
Romidepsin (FK228) and its analogs directly inhibit PI3K activity and potently induce apoptosis as HDAC/PI3K dual inhibitors
Cancer Science   103 1994-2001   2012   [Refereed]